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Summary The effect of combining photodynamic therapy (PDT) and bioreductive drugs has been investi-
gated using the RIF-1 experimental murine tumour. Light was delivered interstially to the tumour at 675 nm
using a single optical fibre attached to an argon-ion dye laser. The photosensitizer was disulphonated
aluminium phthalocyanine (AlS2Pc) and the bioreductive drugs were the dual function nitroimidazole
RSU1069 and its pro-drug RB6145. Varying the time between administration of the photosensitizer and light
delivery (TL) from 30 min to 24 h had little influence on the extent of the anti-tumour effect of PDT alone, as
measured by the regrowth delay endpoint. When the bioreductive drug was included in the treatment,
administered 20 min before light irradation, regrowth delay was greatly increased. The effectiveness of the
combined treatment was optimum for short values of TL (about 1 h).
Fluorescence microscopy was used to investigate the distribution of the photosensitizer within the tumours.
This showed that the compound was mainly confined to the tumour vasculature over the first few hours
post-treatment. The high efficacy of the combined treatment of PDT and bioreductive drugs for short values of
TL suggest that photodynamic action, during the period when the photosensitizer AlS2Pc is confined to the
vasculature, enhances the severity of tumour hypoxia which is sufficient to induce activation of the bioreduc-
tive drugs.
This paper described studies on combining photodynamic
therapy (PDT) and bioreductive drugs in the treatment of an
experimental murine tumour. Bioreductive drugs are agents
that are converted by metabolic reduction to form highly
active cytotoxins. These drugs have potential applications in
cancer therapy when used with other cytotoxic drugs or with
radiotherapy (see Adams & Stratford, 1992).
Since bioreductive drugs are usually activated to a cyto-
toxic product under hypoxic conditions, their activity can
often be enhanced in vivo when used together with treatments
that enhance the depth and duration of hypoxia in solid
tumours. Examples of this approach include the combination
of bioreductive drugs with agents that:
1. Reduce blood flow e.g. clamping (Bremner et al., 1990),
5-hydroxytryptamine (Chaplin, 1986) and hydralazine
(Brown, 1987; Chaplin & Acker, 1987)
2. Increase the oxygen affinity of haemoglobin e.g. BW12C
(Adams et al., 1989).
3. Cause haemorrhagic necrosis, e.g. flavone acetic acid
(Sun & Brown, 1989; Edwards et al., 1991), tumour
necrosis factor (Edwards et al., 1991) and interleukin-2
(Braunschweiger et al., 1988).
Part of the mechanism of the anti-tumour effect of PDT is
believed to be damage to the tumour vasculature (Henderson
et al., 1985; Star et al., 1986; Nelson et al., 1988) which
causes the reduction in the supply of oxygen and other
nutrients to the tumour tissue. A widely proposed mechanis-
tic pathway for cellular destruction with PDT is via the
photoactivation of the photosensitiser in the presence of
oxygen which results in the generation of highly reactive
cytotoxic species including singlet oxygen (Weishaupt et al.,
1976; Spikes, 1986; van Lier, 1990).
Chapman and colleagues were the first to use a bioreduc-
tive agent (misonidazole) in an attempt to exploit tumour
hypoxia induced by PDT. Using a haematoporphyrin deriva-
tive (HpD) photosensitizer, they showed that the addition of
misonidazole 30 min before, or after, light irradiation caused
a significant increase in tumour growth delay and local cure
rate in the rat Dunning R3327-AT and R3327-H tumours
(Gonzalez et al., 1986; Hirsch et al., 1987). Cheng et al.
(1989) also used misonidazole in combination with an HpD
derivative and laser light in the treatment of rat 9L gliosar-
coma tumours. In these experiments, misonidazole was
administered 30-45 min before light treatment which was
given 24 h after HpD. Misonidazole had no significant effect.
The bioreductive drug RSU1069 and its analogue RSU1164,
developed in this laboratory (Ahmed et al., 1986) are more
potent bioreductive drugs than simple nitroimidazoles due to
the incorporation of alkylating functions in the structure.
Both RSU1069 (J.D. Chapman and colleagues, unpublished
observations) and RSU1164 (Henry & Isaacs, 1991) have
been reported to significantly enhance the efficacy of PDT in
experimental tumours when using the partly purified form of
haemotoporphyrin derivative, Photofrin II, as the photosen-
sitiser.
Recent experimental studies with the second generation
photosensitiser, disulphonated aluminium phthalocyanine,
AlS2Pc, using fluorescence microscopy, have shown that this
photosensitiser is highly concentrated in the vasculature of
normal rat colon and bladder 1 h after administration (Chat-
lani et al., 1991; Pope et al., 1991). This has also been shown
for DMH-induced colon tumours in rats (P.T. Chatlani &
A.J. MacRobert, unpublished data). This compound is water
soluble and has a strong absorption maximum at 675 nm
which permits a greater degree of light penetration into tissue
than is possible with the 630 nm light used with Photofin II
(see Tralau et al., 1990). The majority of clinical studies with
PDT employ conditions where the photosensitiser is admin-
istered 24-48 h prior to light, however, the highly specific
localisation in tissue vasculature during the first hour sug-
gested that light delivered to tumours within this time period
after the administration of the photosensitiser might cause
more extensive damage to the vasculature. This might induce,
therefore, a greater degree of tumour hypoxia than would be
achievable if the time period were more prolonged. If so,
combined treatment with a bioreductive drug should be more
effective when the time between the administration of the
photosensitiser and light is short. This hypothesis has been
investigated in the RIF-1 tumour using combined PDT with
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AlS2Pc and the bioreductive drug RSU1069 and its prodrug
RB6145 (Jenkins et al., 1990).
Materials and methods
Tumour models
The RIF-1 murine sarcoma line was maintained as described
previously (Twentyman et al., 1980; Stratford et al., 1988).
Approximately 2 x 105 cells suspended in 0.05 ml PBS were
implanted intradermally (i.d.) into the mid-dorsal pelvic
region of 8-10 week old C3H/He mice (category IV). The
tumour volume at treatment was 100-200mm3.
Tumours were measured in three orthogonal directions at
2-day intervals. The tumour volume was calculated using the
geometric mean of these measurements and assuming spheri-
cal geometry. The regrowth endpoint was the time taken for
the tumours to grow to four times their volume at the start
of treatment.
Drugs
Bioreductive agents RSU1069 is an analogue of the nitro-
imidazole, misonidazole, and contains a weakly basic alky-
lating aziridine group. A dose of 80 mgkg-' in PBS was
used. RB6145 is a haloethylaminohydroxypropyl-2-nitroimid-
azole which acts as a pro-drug for RSU1069 under physio-
logical conditions. A dose of 300 mg kg-' was administered
in acetate buffer (pH 4.5) which minimises its conversion to
RSU1069 prior to injection (Jenkins et al., 1990). Both drugs
were synthesised by Dr M.A. Naylor from the MRC Radio-
biology Unit and administered interperitoneally (i.p.) at
20 ml kg-'. The disulphonated aluminium phthalocyanine
(AlS2Pc) was synthesised, purified and supplied by the
Chemistry Department of Imperial College, London (Amb-
roz et al., 1991; Nuutinen et al., 1991). This compound was
dissolved in isotonic saline and administered intravenously
(i.v.). The injection volume was calculated to achieve a final
dose in the mouse of 4.37 mgkg-'. This represents a dose of
5.7ltmol kg-' which is the same as that used by Tralau et al.
(1987) and Chatlani et al. (1991).
Photodynamic therapy
Light source A Spectra Physics 2016-6 W argon-ion pump-
ed dye-laser was used to generate light at a wavelength of
675 nm. The light was directed down fibre optic cables with a
core diameter of 0.2 mm. The ends of these cables were
cleaved and inserted interstitially into the centre of the
tumours with the fibre positioned parallel to the body of the
mouse. As the average diameter of the tumours was approx-
imately 5 mm, only one fibre was used for each tumour. The
range of total light doses delivered was 10-50 J. The power
density of the light, measured before insertion of the fibre
was varied between 20 and lOOmWcm-2. Light exposures
ranged from 100 to 2,500 s.
Treatment The phthalocyanine was administered (i.v.) fol-
lowed by a dose of light delivered at times (TL) varying from
20 min to 24 h after injection. For the experiments involving
RSU1069 and RB6145, these were always given i.p. 20 min
before light treatment. This time sequence allowed uptake of
bioreductive drugs in the RIF-1 tumour to reach maximum
levels before light treatment. The mice were anaesthetised
0.1 ml injections (i.p.) of a 1:1:2 mixture of Hypnorm:Hyp-
novel:water 10 min before the administration of the light.
One ml of Hypnovel contains 10 mg midazolam base as the
hydrochloride. Hypnorm contains fentanyl citrate at 0.315
mgml-l and fluanison at 10mgml-'. After treatment all
animals were carefully wrapped in aluminium foil and tissue
paper to restrict the amount of body-heat loss which may be
induced by the anaesthetic and/or by the bioreductive drug.
Histology andfluorescence microscopy
In order to determine the uptake and distribution of the
photosensitiser in the RIF-1 sarcoma, tumours were excised
post mortem at various times after the administration of
AlS2Pc. They were snap frozen in liquid nitrogen, and two
serial cryostat sections were taken (10 tm slices) from each
tumour, one section for staining with haematoxylin and eosin
and the other for fluorescence microscopy analysis using a
cooled charge-coupled device (CCD) (Barr et al., 1988; Pope
et al., 1991). A slightly modified technique was used as
described by Chatlani et al. (1991).
Results
Photosensitiser distribution in RIF-J tumours
As discussed earlier, the design of this study was based on
the hypothesis that PDT delivered whilst the sensitiser is
confined mainly to the vasculature, would induce a more
severe degree of hypoxia and therefore should aid the
effectiveness of the bioreductive agent. Some experiments
were carried out using fluorescence microscopy (CCD) in the
RIF tumours of the size range of those used for the PDT
experiments. A series of fluorescent micrographs was pre-
pared for tumours from mice given AlS2Pc at times varying
from 5 min to 24 h after the administration of the photosen-
sitiser. (Two mice were used for each time point.) Examples
of fluoromicrographs for times of 30 min (Figure la), 6 h
(Figure Ic) and 24 h (Figure le) are compared with serial
sections of the same tumour samples stained with haematox-
ylin and eosin (Figure lb,d,f). At 30 min, the fluorescence is
very bright and appears to originate mainly within blood
vessels, with a small amount of fluorescence evident in the
perivascular regions. At 6 h the fluorescence is still mainly
within the blood vessels although there is more fluorescence
diffusely spread throughout the tumour. At 24h the total
level of fluorescence from the frozen sections is about 2-3
times greater than at 30 min. However, the blood vessels are
no longer prominent indicating that there is little or no
photosensitiser remaining within the vasculature. The fluo-
rescence appears to be associated with the surrounding tissue,
particularly within the necrotic regions.
Regrowth delay studies
No effect on the tumour growth is observed for any of the
control groups as shown in Table I. Figure 2 shows regrowth
delay data for tumours treated with PDT at a light dose of
50 J (100 mW/500 s) given from 1 to 24 h after administra-
tion of AlS2Pc. The overall effect on tumour growth shows
little dependence on the value of TL. However when TL is
1 h there is an initial sharp drop in tumour volume which is
not evident in the other growth curves. This size decrease
appears to have little effect on subsequent growth rate. For
TL of 1 h, severe scabbing occurs covering the whole tumour.
This is not observed for values of TL greater than I h.
There is no effect of RSU1069 on tumour response when
given alone or in combination with either AlS2Pc alone or
with light alone (100 mW/500 s) in anaesthetised mice (Table
I). Figure 3 shows the effect of RSU1069, on tumour res-
ponse to PDT. When TL is 24 h, tumour growth is further
retarded relative to that observed for PDT alone when
RSU1069 is included in the treartment, although the effect is
relatively small. In contrast, when TL is reduced to 1 h, this
increased tumour delay induced by RSU1069 is substantially
greater.
Table II shows, for a range of values of TL, the effect on
tumour growth, expressed as the time taken for the tumours
to reach 4 times their initial treatment volume. The light dose
was maintained constant at 100 mW/500 s. RSU1069 poten-
tiates the PDT in all cases but is most effective when TL is
30 min or 1 h. Indeed for the 1 h point, two out of the group
ofeight tumours showed very long regrowth delays (up to 831072 J.C.M. BREMNER et al.
Figure 1 Examples of fluorescence micrographs (10jam) of RIF-1 tumours imaged using a CCD device are shown at 30 min a, 6 h
c, and 24 h e, after the administration of AlS2Pc. The colour scale is shown at the top of the micrograph with the maximum
fluorescence being represented as white and the minimum as black. Serial sections of the same tumours stained with haematoxylin
and eosin are also showed (b, d, f). The boxes delineate identifiable blood vessels.
days). This accounts for the large range in delay values for
this group as is shown in Table II.
It is possible to vary the total light dose (TD) and dose
rate by changing the parameters of the light source power (P)
and total treatment time (T) since TD = P x T. For power
values of 20, 40, 60, 80 or 100 mW, exposure times varying
from 100 to 2,500 s were used to obtain a range in total
doses of 10-50 J. Results showing the effect of RSU1069,
when TL is 1 h, are plotted as cumulative frequency curves in
Figure 4. This shows the percentage of tumours that have
grown to four times their initial treatment volume plotted
against the number of days after treatment. This type of plot
allows all the animals in a group to be used in the analysis,
even those that are 'cured' i.e. that have no evidence of local
tumour recurrence up to 160 days after treatment. Each plot
contains data from a minimum of six animals. In the groups
receiving PDT alone, for each value of power, an increase in
the total dose from 10 J to 50 J causes a small but observable
increase in effect. However, when RSU1069 is administered
20 min before light exposure, the growth of the tumour is
greatly retarded for total light doses in excess of 30 J. Some
long-term cures (up to 33.3%) were obtained in groups
treated with doses of 30-50J. There was no trend showing
any influence of dose rate over the power range of 20-100
mW either with, or without, RSU1069.
For comparison, the potentiating effect of RB6145 was
investigated for a total light dose of 30 J (60 mW/500 s). The
cumulative frequency data in Figure 5 show that this agent,
when administered at its maximum tolerated dose (MTD) of
300 mg kg-' (i.p.), also substantially enhances PDT.
Discussion
The following main conclusions can be drawn from the
results of this study:PHOTODYNAMIC THERAPY AND BIOREDUCTIVE DRUGS 1073
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Figure 2 Tumour growth curves showing the effect of varying
TL in groups of animals receiving a PDT dose of 100 mW/500 s.
Mean tumour size (expressed as GMD)± s.e.m. is plotted against
the number of days after treatment.
1. AlS2Pc is an effective photosensitiser for the RIF-1
tumour when used at a dose of 4.37 mgkg' admini-
stered from 20 min to 24 h before laser treatment.
2. With PDT alone, for a dose of 50 J, there is little effect
of varying TL from 1 h to 24 h on the efficacy of
treatment although the effect is significantly greater for
a shorter delay time of 30 min.
3. RSU1069 greatly potentiates the effect of PDT for
values of TL between 30 min and 6 h. RB6145, a pro-
drug for RSU1069 also potentiates PDT.
4. For the optimum value of TL of 1 h, some tumour
cures were obtained in groups of mice treated with PDT
and RSU1069 at light doses of 30 J and above.
5. There is no significant trend with dose rate over the
power range 20-100 mW.
Distribution kinetics ofthephotosensitiser within the tumour
There is a 2-3 fold increase in total fluorescence from the
tumour sections taken between 30 min and 24 h after injec-
tion, which indicates a gradual build up of the photosen-
0 10 20 30 40
Days after 100 mW/500 s
Figure 3 Tumour growth curves showing the increased effect
induced by RSU1069 (80mg kg-') when administered 20 min
prior to a light irradiation dose of 100 mW/500 s. The results are
shown for groups with a TL of 1 h (O *) and 24 h (A A).
Closed and open symbols represent data from groups with PDT
alone and PDT + RSU1069 respectively.
sitiser within the tumour tissue. The histological preparations
in Figure 1 show that the distribution of the photosensitiser
between the vascular and perivascular regions varied con-
siderably over a 24 h period. Between 30 min and 6 h, the
drug appears to be mainly confined within the vasculature of
the tumour. This is consistent with previous findings showing
that AlS2Pc is at maximum levels within blood vessels of the
colon (Chatlani et al., 1991) and the DMH-induced colonic
rat tumours (P.T. Chatlani & A.J. MacRobert, unpublished
data) at 1 h after administration. The fluorescent micro-
graphs in Figure show that in the RIF-1 tumour there is
little or no photosensitiser detectable within the blood vessels
at 24 h post-administration. This data agrees with that of
Chan et al. (1990) who showed a 10-fold reduction of AlS2Pc
in the plasma from 3 to 24 h after administration. Although
it is not possible, from these micrographs, to determine
precisely in which cells in the RIF-I tumour the AlS2Pc is
located at 24 h, there is evidence that cells of different types,
Table I Time in daysforcontrol tumours to reach four times theirinitial volume in anaesthetised mice.
The numbers of mice and the range in values are indicated for each group
No RSUJ069 +RSU1069
Growth Growth
TL time±s.e. Nos. Range time±s.e. Nos. Range
Untreated control 5.4±0.2 10 4.8-6.1 6.2±0.6 6 5.1-8.5
Anaesthetised control 5.2±0.3 10 4.3-7.3 6.6±0.7 7 4.6-9.3
AlS2Pc alone 6.1±0.8 8 3.2-8.5 5.6±0.6 6 4.8-6.9
Light alone 100 mW/500s 6.2±0.2 6 5.7-7.1 6.1±0.5 6 5.6-7.0
Table II Time in days for tumours to reach four times their initial volume as a function of the time
between administration ofthe photosensitiser and the light irradiation (TL). The numbers ofmice and
the range in values are given for each group. Light doses in all cases was 100 mW for 500 s
No RSUJ069 +RSU1069
Growth Growth
TL time±s.e. Nos. Range time±s.e. Nos. Range
Anaethetised control 5.2±0.3 10 4.3-7.3 6.6±0.7 7 4.6-9.3
20 min 19.1± 1.0 6 16.1-22.4 20.0± 1.2 8 16.5-26.5
30 min 23.1± 1.0 11 15.2-33.6 35.4± 1.2 10 25.9-44.9
1 h 15.0± 1.2 7 9.7-18.3 34.3± 12.7 8 14.5-83.2
2 h 12.6± 1.0 6 8.6-15.7 24.2±2.3 6 15.1-30.0
4 h 11.2±0.4 6 9.3± 12.6 21.3± 1.6 12 12.4-27.9
6 h 11.3±0.4 6 10.3-13.3 19.9± 1.4 6 13.1-22.8
24 h 17.9± 1.7 10 10.7-29.9 21.1± 1.0 15 15.1 -29.9
.
11074 J.C.M. BREMNER et al.
-1069 +1069
20 mW
100
80t
40 mW
40 mI2 6lm
20
0
X 100
c 80
a)
20
40
100-
80
60 20 40 60 80 00 0 20 40 60 80 080mW
40
20
0
100 g
80
~~~~~~~~~~100 mW
20
0
0 20 40 60 80 100 0 20 40 60 80 100
Days after treatment
Figure 4 The cumulative frequency of tumours that have reached four times their initial tumour volume as a function of the
number of days after treatment. For each light power (20, 40, 60, 80 and 100 mW) the exposure times are altered to give total light
doses of 10 J (A), 20 J (0), 30 J (O), 40 J (X) and 50 J (U). The results are shown for groups with or without RSUl069
(80mg kg-'). In all cases the value of TL is h.
including macrophages, can differ in their rates of uptake and
in their retention of photosensitisers (Chan et al., 1988;
Henderson & Bellnier, 1989; Korbelik et al., 1991). This may
be of importance for the overall tumour response to PDT for
a particular tumour type.
As stated earlier, the rationale behind the combined use of
PDT and bioreductive drugs is to exploit the tumour hypoxia
induced by PDT in order to activate the cytotoxic action of
bioreducible drugs. Earlier studies on combining PDT and
the bioreductive drugs, misonidazole, etanidazole, RSU1069
and RSU1 164, employed treatments where the interval
between administration of the photosensitiser and laser treat-
ment was between 4 and 24 h. In the paper by Gonzalez et
al. (1986) and (Hirsch et al. (1987) where they used a 4 h
interval, this coincided with the maximum uptake of the
Photofrin II within the whole tumour.
In the present study, the potentiating effect of the bio-
reductive drug RSU1069 on PDT with AlS2Pc is clearly
optimum when the treatment interval is very short i.e. from
0.5 to 1 h. The fact that this corresponds to the period when
the concentration of the phthalocyanine is mainly confined to
the tumour vasculature is consistent with induction of severe
tumour hypoxia by direct damage to endothelial cells within
the tumour and/or with other vascular-mediated effects (see
Henderson & Dougherty, 1992). The increased effect of PDT
alone when TL is 24 h compared to that at 1 h may be due to
a slightly increased efficacy of PDT because of the higher
concentration of the photosensitiser and its wider distribution
throughout the tumour. However, the potentiating effect of
the bioreductive drug is much less at 24 h, presumably
because the tumour hypoxia is less severe under these condi-
tions than it is when the treatment interval is only 1 h.
Induction oftumour hypoxia
As indicated in the Introduction, various methods have been
used to investigate the effect ofmanipulating tumour hypoxia
on the efficacy of the anti-tumour effects of bioreductive
drugs. Figure 6, collects data from the other studies with the
RIF-1 tumour carried out in this laboratory, where RSU1069
has been used in combination with different methods for
enhancing tumour hypoxia, and compares these with thePHOTODYNAMIC THERAPY AND BIOREDUCTIVE DRUGS 1075
100 1
~-. 80 /
a)D 60
40-
E
~20-
a
0 10 20 30 40 50 60
Days after 60 mW/500 s
Figure 5 The cumulative frequency of tumours which have
reached four times their initial tumour volume plotted against the
number of days after treatment. TL is 1 h. Tumours were either
treated with PDT alone at a dose of 60 mW/500 s (30 J) (A) or
with the addition of RB6145 (300mg kg-') (*) or RSU1069
(80 mg kg-') (V) 20 min prior to light irradiation. 0, untreated
controls.
results of the present study.
Some retardation of tumour growth is evident in mice
treated with the vasoactive drug, hydralazine (Bremner et al.,
1990) and with flavone acetic acid but not with the haema-
globin left-shifter BW12C (Bremner, unpublished results).
However, a large effect is observed when the tumour blood
supply is occluded by mechanical clamping. Under these
conditions, some tumour cures were observed (Bremner et
al., 1990).
The inhibitory effect of PDT in combination with
RSU1069 on tumour growth is clearly as effective as the
clamping treatment. This suggests that the severity of the
tumour hypoxia is similar for both types of treatment,
although the duration may be different.
Tumour selectivity
Practical application of PDT rests, as with all treatments, on
a positive degree of tumour selectivity. In PDT, particularly
with haematoporphyrin derivative, such selectivity has been
based on evidence that drug levels in tumours are often
higher than those in normal tissues at 24 h post drug treat-
ment (Wharen et al., 1983). Recent studies using a mixed
sulphonated sample of aluminium phthalocyanines, however,
suggest that the uptake in tumour relative to that in normal
tissue (other than for tumours within the CNS) at 24-48 h
30**
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Figure 6 A bar-graph showing the time taken for RIF-I
tumours to reach four times their initial volume, with (D) and
without (O) RSU1069 after: a, clamping for 90 min (Bremner et
al., 1990); b, 5 mgkg-I of hydralazine (i.v.) (Bremner et al.,
1990); c, 70mgkg-I BWI12c (i.v.) (Bremner, J.C.M., unpublished
data); d, 200mgkg-' FAA (i.v.) (Edwards et al., 1991); and e, a
PDT dose of 40 J (80 mW/500 s) - see discussion. The asterisk
indicates groups containing animals with cured tumours.
may be as low as 2:1 (Tralau et al., 1987; 1990). Large ratios
of up to 28: 1, found for tumours within the CNS, are
probably due to the inability of the phthalocyanines to pass
through the blood-brain barrier, resulting in very little
uptake in normal brain tissue.
The extent of normal tissue damage caused by the com-
bined treatment of PDT and bioreductive drugs is not yet
known and it could limit the overall effectiveness of this
approach. Solid tumours are overall significantly more
hypoxic than normal tissues, therefore, reduction in oxygena-
tion induced by PDT is more likely to create an environment
in tumours suitable for the activation of bioreductive drugs
than is likely to occur in normal tissues. While systematic
studies of normal tissue damage in appropriate model
systems are required, it is encouraging that in the present
study, no increase of PDT damage was observed in the
normal skin surrounding the tumours when RSU1069 was
used.
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